

Sheryl A Zelenitsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8086656/publications.pdf>

Version: 2024-02-01

79
papers

4,470
citations

159585
30
h-index

106344
65
g-index

81
all docs

81
docs citations

81
times ranked

4247
citing authors

#	ARTICLE	IF	CITATIONS
1	Ceftazidime-Avibactam: a Novel Cephalosporin/ β -lactamase Inhibitor Combination. <i>Drugs</i> , 2013, 73, 159-177.	10.9	362
2	Imipenem+Relebactam and Meropenem+Vaborbactam: Two Novel Carbapenem- β -Lactamase Inhibitor Combinations. <i>Drugs</i> , 2018, 78, 65-98.	10.9	291
3	New Lipoglycopeptides. <i>Drugs</i> , 2010, 70, 859-886.	10.9	280
4	Ceftolozane/Tazobactam: A Novel Cephalosporin/ β -Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2014, 74, 31-51.	10.9	279
5	Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> , 2019, 79, 271-289.	10.9	274
6	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. <i>Drugs</i> , 2016, 76, 567-588.	10.9	199
7	Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 459-473.	4.4	171
8	Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia. <i>Annals of Pharmacotherapy</i> , 2005, 39, 32-38.	1.9	168
9	Analysis of microbiological trends in peritoneal dialysis-related peritonitis from 1991 to 1998. <i>American Journal of Kidney Diseases</i> , 2000, 36, 1009-1013.	1.9	166
10	Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens. <i>Drugs</i> , 2015, 75, 253-270.	10.9	140
11	Treatment and outcome of <i>Pseudomonas aeruginosa</i> bacteraemia: an antibiotic pharmacodynamic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 52, 668-674.	3.0	130
12	Antibiotic Pharmacodynamics in Surgical Prophylaxis: an Association between Intraoperative Antibiotic Concentrations and Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3026-3030.	3.2	124
13	Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1476-1481.	3.2	114
14	Ceftaroline. <i>Drugs</i> , 2009, 69, 809-831.	10.9	114
15	Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. <i>Clinical Pharmacokinetics</i> , 2015, 54, 783-795.	3.5	107
16	In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of <i>Candida</i> species, <i>Cryptococcus neoformans</i> , <i>Blastomyces dermatitidis</i> , and <i>Aspergillus</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 863-865.	3.2	104
17	Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. <i>Cmaj</i> , 2010, 182, 357-363.	2.0	99
18	Vancomycin pharmacodynamics and survival in patients with methicillin-resistant <i>Staphylococcus aureus</i> -associated septic shock. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 255-260.	2.5	99

#	ARTICLE	IF	CITATIONS
19	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011, 37, 632-638.	8.2	90
20	Aminoglycoside-Induced Vestibular Injury: Maintaining a Sense of Balance. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1282-1289.	1.9	72
21	Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of <i>Stenotrophomonas maltophilia</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 39-43.	1.8	69
22	Support for higher ciprofloxacin AUC ₂₄ /MIC targets in treating Enterobacteriaceae bloodstream infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1725-1732.	3.0	69
23	Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. <i>Drugs</i> , 2020, 80, 285-313.	10.9	60
24	Adequacy of a Vancomycin Dosing Regimen in Patients Receiving High-Flux Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2005, 46, 681-687.	1.9	58
25	Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 343-349.	3.0	47
26	A prospective, randomized, double-blind study of single high dose versus multiple standard dose gentamicin both in combination with metronidazole for colorectal surgical prophylaxis. <i>Journal of Hospital Infection</i> , 2000, 46, 135-140.	2.9	40
27	Evaluating Ciprofloxacin Dosing for <i>Pseudomonas aeruginosa</i> Infection by Using Clinical Outcome-Based Monte Carlo Simulations. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4009-4014.	3.2	40
28	Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. <i>Drugs</i> , 2016, 76, 1737-1757.	10.9	38
29	Microbiological Trends and Antimicrobial Resistance in Peritoneal Dialysis-Related Peritonitis, 2005 to 2014. <i>Peritoneal Dialysis International</i> , 2017, 37, 170-176.	2.3	35
30	Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1024-1026.	3.0	34
31	Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis. <i>Clinical Infectious Diseases</i> , 2012, 55, 527-533.	5.8	30
32	In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant <i>Candida</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 2576-2578.	3.2	28
33	Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant <i>Enterococcus faecium</i> strains. <i>Antimicrobial Agents and Chemotherapy</i> , 1997, 41, 1407-1408.	3.2	26
34	Challenging the Current Treatment Paradigm for Methicillin-Resistant <i>Staphylococcus Epidermidis</i> Peritonitis in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 335-338.	2.3	26
35	An in vitro evaluation of the antibiotic/heparin lock to sterilize central venous haemodialysis catheters. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 693-696.	3.0	25
36	Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant <i>Staphylococcus aureus</i> , heteroresistant vancomycin-intermediate <i>S. aureus</i> , vancomycin-intermediate <i>S. aureus</i> and vancomycin-resistant <i>S. aureus</i> using an in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1301-1305.	3.0	24

#	ARTICLE	IF	CITATIONS
37	Using Curriculum Mapping to Engage Faculty Members in the Analysis of a Pharmacy Program. American Journal of Pharmaceutical Education, 2014, 78, 139.	2.1	24
38	Altered denA and anr gene expression in aminoglycoside adaptive resistance in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 1997, 40, 371-376.	3.0	23
39	Synergy of an Investigational Glycopeptide, LY333328, with Once-Daily Gentamicin against Vancomycin-Resistant Enterococcus faecium in a Multiple-Dose, In Vitro Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 1999, 43, 592-597.	3.2	22
40	Integrating pharmacokinetics, pharmacodynamics and MIC distributions to assess changing antimicrobial activity against clinical isolates of Pseudomonas aeruginosa causing infections in Canadian hospitals (CANWARD). Journal of Antimicrobial Chemotherapy, 2013, 68, i67-i72.	3.0	21
41	Treatment Strategies for Recurrent Clostridium difficile Infection. Canadian Journal of Hospital Pharmacy, 2013, 66, 361-8.	0.1	21
42	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2021, 81, 233-256.	10.9	20
43	AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model. Journal of Antimicrobial Chemotherapy, 2003, 51, 905-911.	3.0	19
44	Antimicrobial Prophylaxis for Patients Undergoing Cardiac Surgery: Intraoperative Cefazolin Concentrations and Sternal Wound Infections. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
45	Phenazopyridine in Urinary Tract Infections. Annals of Pharmacotherapy, 1996, 30, 866-868.	1.9	18
46	Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy, 2018, 73, 1888-1894.	3.0	18
47	Susceptibilities of Candida Species Isolated from the Lower Gastrointestinal Tracts of High-Risk Patients to the New Semisynthetic Echinocandin LY303366 and Other Antifungal Agents. Antimicrobial Agents and Chemotherapy, 1998, 42, 2446-2448.	3.2	16
48	Effect of Ethanol/Trisodium Citrate Lock on Microorganisms Causing Hemodialysis Catheter-Related Infections. Journal of Vascular Access, 2007, 8, 262-267.	0.9	15
49	Targeted benefits of prolonged-infusion piperacillin-tazobactam in an <i>in vitro</i> infection model of <i>Pseudomonas aeruginosa</i> . Journal of Chemotherapy, 2016, 28, 390-394.	1.5	15
50	Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. Journal of Antimicrobial Chemotherapy, 2018, 73, 768-771.	3.0	14
51	Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. Annals of Pharmacotherapy, 2018, 52, 965-973.	1.9	14
52	Antibiotic tolerance of peritoneal bacterial isolates in dialysis fluids. Journal of Antimicrobial Chemotherapy, 2002, 49, 863-866.	3.0	13
53	Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. Clinical Pharmacokinetics, 2020, 59, 327-334.	3.5	13
54	Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. Journal of Antimicrobial Chemotherapy, 2016, 71, 2902-2908.	3.0	12

#	ARTICLE	IF	CITATIONS
55	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. <i>Drugs</i> , 2022, 82, 533-557.	10.9	12
56	Preferential Emergence of Reduced Vancomycin Susceptibility in Health Care-Associated Methicillin-Resistant <i>Staphylococcus aureus</i> Isolates during Continuous-Infusion Vancomycin Therapy in an <i>In Vitro</i> Dynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3627-3630.	3.2	11
57	Simulation of cyclic reprocessing buildup on reused medical devices. <i>Computers in Biology and Medicine</i> , 2009, 39, 568-577.	7.0	10
58	Successful Treatment of Pulmonary Blastomycosis with Continuously Infused Amphotericin B Deoxycholate After Failure with Liposomal Amphotericin B. <i>Annals of Pharmacotherapy</i> , 2013, 47, e26-e26.	1.9	9
59	An Evaluation of an Optimal Sampling Strategy for Meropenem in Febrile Neutropenics. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 832-835.	2.0	7
60	Effect of an ethanol/trisodium citrate hemodialysis catheter locking solution on isolates of <i>Candida albicans</i> . <i>Hemodialysis International</i> , 2008, 12, 342-347.	0.9	7
61	Multifaceted antibiotic treatment analysis of methicillin-sensitive <i>Staphylococcus aureus</i> bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 674-679.	2.5	7
62	Challenging the current treatment paradigm for methicillin-resistant <i>Staphylococcus epidermidis</i> peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2002, 22, 335-8.	2.3	7
63	Pharmacodynamic Profiling of Antimicrobials against Gram-negative Respiratory Isolates from Canadian Hospitals. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, 132-136.	1.9	6
64	In vitro antifungal activity of BMS-181184 against systemic isolates of <i>Candida</i> , <i>Cryptococcus</i> , and <i>Blastomyces</i> species. <i>Diagnostic Microbiology and Infectious Disease</i> , 1997, 28, 179-182.	1.8	5
65	Once versus Thrice Daily Tobramycin Alone and in Combination with Ceftazidime, Ciprofloxacin and Imipenem in an in vitro Pharmacodynamic Model. <i>Chemotherapy</i> , 1998, 44, 1-6.	1.6	5
66	Peritoneal Fluid Titer Test for Peritoneal Dialysis-Related Peritonitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1719-1726.	3.2	5
67	Effect of antibiotic sequence on combination regimens against <i>Pseudomonas aeruginosa</i> in a multiple-dose, in vitro infection model. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 67-70.	1.8	5
68	Bayesian Pharmacokinetic Analysis of a Gentamicin Nomogram in Neonates: A Retrospective Study. <i>Current Therapeutic Research</i> , 2003, 64, 178-188.	1.2	4
69	A reevaluation of empiric therapy for peritoneal dialysis-related peritonitis. <i>American Journal of Kidney Diseases</i> , 2004, 44, 559-561.	1.9	4
70	Evaluation of the Research Grant Program of the Foundation of the Canadian Society of Hospital Pharmacists, 1995-2008. <i>Canadian Journal of Hospital Pharmacy</i> , 2011, 64, 399-404.	0.1	4
71	No role for patient body weight on renal function assessment for drug dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1802-1811.	3.0	3
72	Should IV Antibiotics Be Administered by Prolonged Infusion?. <i>Canadian Journal of Hospital Pharmacy</i> , 2010, 63, 246-9.	0.1	2

#	ARTICLE	IF	CITATIONS
73	An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis. American Journal of Health-System Pharmacy, 2022, , .	1.0	2
74	Therapeutic Drug Monitoring of Vancomycin in Adult Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia or Pneumonia. Canadian Journal of Hospital Pharmacy, 2021, 74, 334-343.	0.1	1
75	Pharmacodynamics of Antimicrobial Prophylaxis in Cardiac Surgery: Association Between Intraoperative Cefazolin Concentrations and Postoperative Infections. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
76	Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass—authors' response. Journal of Antimicrobial Chemotherapy, 2018, 73, 2588-2588.	3.0	0
77	Clinical Blood Isolates from Hemodialysis Patients: Distribution of Organisms and Antimicrobial Resistance, 2007-2014. Canadian Journal of Hospital Pharmacy, 2020, 73, 266-271.	0.1	0
78	Clinical Blood Isolates from Hemodialysis Patients: Distribution of Organisms and Antimicrobial Resistance, 2007–2014. Canadian Journal of Hospital Pharmacy, 2020, 73, .	0.1	0
79	A reevaluation of empiric therapy for peritoneal dialysis-related peritonitis. American Journal of Kidney Diseases, 2004, 44, 559-561.	1.9	0